These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35155874)

  • 1. Alport Syndrome With Kidney Cysts Is Still Alport Syndrome.
    Savige J; Mack H; Thomas R; Langsford D; Pianta T
    Kidney Int Rep; 2022 Feb; 7(2):339-342. PubMed ID: 35155874
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney transplantation in patients with alport syndrome.
    Mojahedi MJ; Hekmat R; Ahmadnia H
    Urol J; 2007; 4(4):234-7. PubMed ID: 18270949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.
    Guo J; Song W; Boulanger J; Xu EY; Wang F; Zhang Y; He Q; Wang S; Yang L; Pryce C; Phillips L; MacKenna D; Leberer E; Ibraghimov-Beskrovnaya O; Ding J; Liu S
    Hum Gene Ther; 2019 Jul; 30(7):865-881. PubMed ID: 30808234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.
    Li B; Zhang Y; Wang F; Nair V; Ding F; Xiao H; Yao Y; Kretzler M; Ju W; Ding J
    Pediatr Nephrol; 2018 Oct; 33(10):1731-1739. PubMed ID: 29948307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
    Temme J; Kramer A; Jager KJ; Lange K; Peters F; Müller GA; Kramar R; Heaf JG; Finne P; Palsson R; Reisæter AV; Hoitsma AJ; Metcalfe W; Postorino M; Zurriaga O; Santos JP; Ravani P; Jarraya F; Verrina E; Dekker FW; Gross O
    Clin J Am Soc Nephrol; 2012 Dec; 7(12):1969-76. PubMed ID: 22997344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of kidney transplantation in Alport syndrome compared with other forms of renal disease.
    Kelly YP; Patil A; Wallis L; Murray S; Kant S; Kaballo MA; Casserly L; Doyle B; Dorman A; O'Kelly P; Conlon PJ
    Ren Fail; 2017 Nov; 39(1):290-293. PubMed ID: 27917694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin contributes to kidney disease progression in Alport syndrome.
    Jarad G; Knutsen RH; Mecham RP; Miner JH
    Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.
    Yoshioka K; Hino S; Takemura T; Maki S; Wieslander J; Takekoshi Y; Makino H; Kagawa M; Sado Y; Kashtan CE
    Am J Pathol; 1994 May; 144(5):986-96. PubMed ID: 8178947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alport Syndrome Classification and Management.
    Warady BA; Agarwal R; Bangalore S; Chapman A; Levin A; Stenvinkel P; Toto RD; Chertow GM
    Kidney Med; 2020; 2(5):639-649. PubMed ID: 33094278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.
    Akihisa T; Sato M; Wakayama Y; Taneda S; Horita S; Hirose O; Makabe S; Kataoka H; Mori T; Sohara E; Uchida S; Nitta K; Mochizuki T
    Kidney Med; 2019; 1(6):391-396. PubMed ID: 32734219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Incidence of BK Virus Nephropathy in Pediatric Kidney Allograft Recipients with Alport Syndrome.
    Cho YH; Hyun HS; Park E; Moon KC; Min SI; Ha J; Ha IS; Cheong HI; Ahn YH; Kang HG
    J Clin Med; 2019 Apr; 8(4):. PubMed ID: 30978953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.
    Mallett A; Tang W; Clayton PA; Stevenson S; McDonald SP; Hawley CM; Badve SV; Boudville N; Brown FG; Campbell SB; Johnson DW
    Nephrol Dial Transplant; 2014 Dec; 29(12):2277-86. PubMed ID: 25061124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosing Alport Syndrome: Lessons from the Pediatric Ward.
    Vos P; Zietse R; van Geel M; Brooks AS; Cransberg K
    Nephron; 2018; 140(3):203-210. PubMed ID: 30212818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early RAAS Blockade Exerts Renoprotective Effects in Autosomal Recessive Alport Syndrome.
    Uchida N; Kumagai N; Nozu K; Fu XJ; Iijima K; Kondo Y; Kure S
    Tohoku J Exp Med; 2016 Nov; 240(3):251-257. PubMed ID: 27904025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome.
    Shaw EA; Colville D; Wang YY; Zhang KW; Dagher H; Fassett R; Guymer R; Savige J
    Nephrol Dial Transplant; 2007 Jan; 22(1):104-8. PubMed ID: 17071739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural-functional relationships in Alport syndrome.
    Kim KH; Kim Y; Gubler MC; Steffes MW; Lane PH; Kashtan CE; Crosson JT; Mauer SM
    J Am Soc Nephrol; 1995 Mar; 5(9):1659-68. PubMed ID: 7780054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alport syndrome--insights from basic and clinical research.
    Kruegel J; Rubel D; Gross O
    Nat Rev Nephrol; 2013 Mar; 9(3):170-8. PubMed ID: 23165304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular diagnosis of Alport syndrome.
    Kashtan CE
    Proc Assoc Am Physicians; 1995 Oct; 107(3):306-13. PubMed ID: 8608415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
    Chertow GM; Appel GB; Andreoli S; Bangalore S; Block GA; Chapman AB; Chin MP; Gibson KL; Goldsberry A; Iijima K; Inker LA; Knebelmann B; Mariani LH; Meyer CJ; Nozu K; O'Grady M; Silva AL; Stenvinkel P; Torra R; Warady BA; Pergola PE
    Am J Nephrol; 2021; 52(3):180-189. PubMed ID: 33789284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation.
    Hudson BG; Kalluri R; Gunwar S; Weber M; Ballester F; Hudson JK; Noelken ME; Sarras M; Richardson WR; Saus J
    Kidney Int; 1992 Jul; 42(1):179-87. PubMed ID: 1635348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.